{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:27:28Z","timestamp":1791919648433,"version":"4.3.4"},"reference-count":300,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019556","name":"Department of Mechanical Engineering, University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1745302"],"award-info":[{"award-number":["1745302"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jconrel.2022.10.043","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T05:19:24Z","timestamp":1668403164000},"page":"840-860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["The past, present, and future of chemotherapy with a focus on individualization of drug dosing"],"prefix":"10.1016","volume":"352","author":[{"given":"Louis","family":"DeRidder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Rubinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Traverso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.10.043_bb0005","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1245\/s10434-009-0886-6","article-title":"Ancient greek and greco\u2013roman methods in modern surgical treatment of cancer","volume":"17","author":"Papavramidou","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0010","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"American Association for Cancer Research"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0015","first-page":"391","article-title":"Origins of cancer therapy","volume":"74","author":"Papac","year":"2001","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0025","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41571-019-0299-9","article-title":"Towards personalized treatment for early stage HER2-positive breast cancer","volume":"17","author":"Goutsouliak","year":"2020","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0030","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1148\/50.3.387","article-title":"Chemotherapy in Human Lymphomas, Leukemias, and Allied Disorders of the Hemopoietic System","volume":"50","author":"Spurr","year":"1948","journal-title":"Radiology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0040","first-page":"1","article-title":"The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus)","volume":"3","author":"Coley","year":"1910","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0045","first-page":"154","article-title":"The Toxins of William B. Coley and the Treatment of Bone and Soft-Tissue Sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthop J"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/1948-5956.100000e2","article-title":"History of Cancer, Ancient and Modern Treatment Methods","volume":"1","author":"Sudhakar","year":"2009","journal-title":"J Cancer Sci Ther"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0055","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7150\/ijms.3635","article-title":"Cancer and Radiation Therapy: Current Advances and Future Directions","volume":"9","author":"Baskar","year":"2012","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0060","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jinf.2004.05.022","article-title":"The contributions of Paul Ehrlich to infectious disease","volume":"54","author":"Gensini","year":"2007","journal-title":"Journal of Infection"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0065","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1258\/jrsm.2009.09k036","article-title":"The introduction of \u2018chemotherapy\u2019 using arsphenamine \u2013 the first magic bullet","volume":"102","author":"Williams","year":"2009","journal-title":"J R Soc Med"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0070","first-page":"497-508.3","article-title":"The Blood and Bone Marrow in Yelloe Cross Gas (Mustard Gas)","volume":"40","author":"Krumbhaar","year":"1919","journal-title":"Poisoning. J Med Res"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.1919.26110010018009f","article-title":"R\u00f4le of the blood and the bone marrow in certain forms of gas poisoning: i. peripheral blood changes and their significance","volume":"72","author":"Krumbhaar","year":"1919","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0080","first-page":"293","article-title":"Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0085","author":"Milestones in Cancer Research and Discovery - National Cancer Institute"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0090","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)","volume":"238","author":"Sidney Farber","year":"1948","journal-title":"NEJM"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0095","unstructured":"Major Cancer Milestones in History, From ASCO\u2019s CancerProgress.Net - The ASCO Post. https:\/\/ascopost.com\/issues\/march-15-2014\/major-cancer-milestones-in-history-from-asco-s-cancerprogressnet\/."},{"key":"10.1016\/j.jconrel.2022.10.043_bb0100","series-title":"Actinomycin D in Childhood Cancer","author":"Pinkel","year":"1959"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0105","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","article-title":"Combination chemotherapy in the treatment of advanced Hodgkin\u2019s disease","volume":"73","author":"Devita","year":"1970","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0110","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(96)91015-6","article-title":"The war on cancer","volume":"347","author":"Sporn","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0115","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/sj.leu.2404756","article-title":"The history of angiogenesis inhibitors","volume":"21","author":"Ribatti","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0120","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor Angiogenesis: Therapeutic Implications","volume":"285","author":"Folkman","year":"1971","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0125","author":"FDA"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: The first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0140","author":"Anastrozole FDA approval"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0145","first-page":"66","article-title":"Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma","volume":"26","author":"Grillo-L\u00f3pez","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0150","unstructured":"FDA. Rituximab FDA Approval Letter. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=103705."},{"key":"10.1016\/j.jconrel.2022.10.043_bb0155","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1586\/era.13.16","article-title":"The first antibody therapy for cancer: a personal experience","volume":"13","author":"Grillo-L\u00f3pez","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0160","series-title":"Trastuzumab, Genentech Herceptin approval letter Ref No. 98-0369","author":"Jay Sigel of FDA","year":"1998"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0165","unstructured":"Drug Approval Package: Gleevec (Imatinib Mesylate) NDA #21-335. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/21335_Gleevec.cfm."},{"key":"10.1016\/j.jconrel.2022.10.043_bb0170","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001\u20132020)","volume":"13","author":"Huang","year":"2020","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0175","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1568009614666140804154511","article-title":"Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System","volume":"14","author":"Dou","year":"2014","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0180","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/phar.1147","article-title":"Anti-angiogenic therapy for cancer: An update","volume":"32","author":"Al-Husein","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0185","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40259-015-0140-7","article-title":"Sipuleucel-T (Provenge(\u00ae))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention","volume":"29","author":"Jaros\u0142awski","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0190","series-title":"FDA","article-title":"Research, C. for B. E. and. PROVENGE (sipuleucel-T)","year":"2019"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0195","unstructured":"FDA. IPILIMUMAB FDA Approval Letter. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=125377."},{"key":"10.1016\/j.jconrel.2022.10.043_bb0200","first-page":"503","article-title":"Ipilimumab (Yervoy) Prolongs Survival In Advanced Melanoma","volume":"37","author":"Fellner","year":"2012","journal-title":"P T"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0205","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0210","first-page":"180","article-title":"Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0215","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0220","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0225","author":"FDA"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0230","unstructured":"FDA. Press Announcements - FDA approval brings first gene therapy to the United States. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm574058.htm (2017)."},{"key":"10.1016\/j.jconrel.2022.10.043_bb0235","unstructured":"Radiopharmaceuticals Emerging as New Cancer Therapy - NCI. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2020\/radiopharmaceuticals-cancer-radiation-therapy (2020)."},{"key":"10.1016\/j.jconrel.2022.10.043_bb0240","series-title":"Research, C. for D. E. and. FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS. FDA","year":"2019"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0245","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0250","unstructured":"Bell, M. FDA Approved Targeted Therapies. Circulogene https:\/\/circulogene.com\/clinicians-and-researchers\/fda-approved-targeted-therapies\/."},{"key":"10.1016\/j.jconrel.2022.10.043_bb0255","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1470-2045(03)01282-8","article-title":"Excisional surgery for cancer cure: therapy at a cost","volume":"4","author":"Coffey","year":"2003","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0260","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/0008-5472.CAN-16-1536","article-title":"Surgery for Cancer: A Trigger for Metastases","volume":"77","author":"Tohme","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0265","doi-asserted-by":"crossref","DOI":"10.21767\/2394-9988.100064","article-title":"Thermal Therapy Modalities for Cancer Treatment: A Review and Future Perspectives","volume":"04","author":"Mellal","year":"2017","journal-title":"International Journal of Applied Science - Research and Review"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0270","series-title":"Chapter 2 \u2013 Antimetabolites","author":"Avenda\u00f1o","year":"2008"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0275","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-Fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2015.00499","article-title":"Thymineless death, at the origin","volume":"6","author":"Guzm\u00e1n","year":"2015","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0285","doi-asserted-by":"crossref","first-page":"8144","DOI":"10.1073\/pnas.94.15.8144","article-title":"Thymineless death in colon carcinoma cells is mediated via Fas signaling","volume":"94","author":"Houghton","year":"1997","journal-title":"PNAS"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0290","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-09-0366","article-title":"Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance","volume":"8","author":"Perez","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0295","series-title":"Biochemistry","author":"Berg","year":"2002"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0300","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104398","article-title":"Irinotecan: 25 years of cancer treatment","volume":"148","author":"Bailly","year":"2019","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0310","article-title":"New insights into the activities and toxicities of the old anticancer drug doxorubicin","author":"van der Zanden","year":"2020","journal-title":"FEBS J"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0315","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/ncomms2921","article-title":"Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin","volume":"4","author":"Pang","year":"2013","journal-title":"Nature Communications"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0320","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The Diagnosis and Treatment of Prostate Cancer: A Review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0325","first-page":"405","article-title":"Endocrine Therapy for Early Breast Cancer: Updated Review","volume":"17","author":"Tremont","year":"2017","journal-title":"Ochsner Journal"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0330","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0335","series-title":"Agents for Chemoprevention and Their Mechanism of Action","author":"Sporn","year":"2003"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0340","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0345","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41397-019-0138-5","article-title":"Cancer\u2019s epigenetic drugs: where are they in the cancer medicines?","volume":"20","author":"Ghasemi","year":"2020","journal-title":"The Pharmacogenomics Journal"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0350","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrg.2016.59","article-title":"The molecular hallmarks of epigenetic control","volume":"17","author":"Allis","year":"2016","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0355","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0360","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00003495-200868040-00009","article-title":"Bevacizumab: a review of its use in metastatic colorectal cancer","volume":"68","author":"McCormack","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0365","author":"Angiogenesis Inhibitors - NCI"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0370","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1200\/JCO.20.00174","article-title":"Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial","volume":"38","author":"Tang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0375","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4161\/mabs.29089","article-title":"Antibodies directed against receptor tyrosine kinases","volume":"6","author":"Fauvel","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0380","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: Treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0385","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0390","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.currproblcancer.2013.06.001","article-title":"US FDA Approved Oral Kinase Inhibitors for the Treatment of Malignancies","volume":"37","author":"Jeong","year":"2013","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0395","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00041","article-title":"Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer","volume":"8","author":"Sia","year":"2020","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0405","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40291-022-00594-2","article-title":"Lutetium Lu 177 Vipivotide Tetraxetan: First Approval","volume":"26","author":"Keam","year":"2022","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.583309","article-title":"New Frontiers in Molecular Imaging Using Peptide-Based Radiopharmaceuticals for Prostate Cancer","volume":"8","author":"Li","year":"2020","journal-title":"Frontiers in Chemistry"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0415","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41551-021-00698-w","article-title":"The evolution of commercial drug delivery technologies","volume":"5","author":"Vargason","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2014.02.006","article-title":"Evolution of implantable and insertable drug delivery systems","volume":"181","author":"Kleiner","year":"2014","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0425","first-page":"742","article-title":"Progress in Nanomedicine: Approved and Investigational Nanodrugs","volume":"42","author":"Ventola","year":"2017","journal-title":"P T"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0430","unstructured":"FDA. Doxil FDA Approval. NDA number: 050718. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=050718."},{"key":"10.1016\/j.jconrel.2022.10.043_bb0435","article-title":"Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England","volume":"29","author":"Cherla","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0440","doi-asserted-by":"crossref","first-page":"71548","DOI":"10.18632\/oncotarget.17742","article-title":"A global comparison of the cost of patented cancer drugs in relation to global differences in wealth","volume":"8","author":"Goldstein","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0445","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0450","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0455","doi-asserted-by":"crossref","DOI":"10.21037\/tcr.2017.10.30","article-title":"Precision dosing of targeted anticancer drugs\u2014challenges in the real world","volume":"6","author":"Kim","year":"2017","journal-title":"Translational Cancer Research"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0460","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: From Rational Design to Clinical Efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"JCO"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0465","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clon.2006.10.010","article-title":"Chemotherapy dosing part I: scientific basis for current practice and use of body surface area","volume":"19","author":"Kaestner","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0470","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1345\/aph.19381","article-title":"The Origin of the \u201cIdeal\u201d Body Weight Equations","volume":"34","author":"Pai","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0475","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/106002807400801104","article-title":"Clinical Pharmacy: Case Studies: Case Number 25 Gentamicin Therapy","volume":"8","author":"McCarron","year":"1974","journal-title":"Drug Intelligence & Clinical Pharmacy"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0480","first-page":"239","article-title":"Prediction of apparent volume of distribution in obesity","volume":"8","author":"Wa","year":"1986","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0485","first-page":"273","article-title":"From Average to Ideal: The Evolution of the Height and Weight Table in the United States, 1836-1943","volume":"31","author":"Czerniawski","year":"2007","journal-title":"Social Science History"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0490","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified Calculation of Body-Surface Area","volume":"317","author":"Mosteller","year":"1987","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0495","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","article-title":"Clinical Calorimetry: Tenth Paper. A formula to estimate the approximate surface area if height and weight be known","volume":"XVII","author":"Du BOIS","year":"1916","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0500","first-page":"853","article-title":"The Use of Body Surface Area as a Criterion of Drug Dosage in Cancer Chemotherapy","volume":"18","author":"Pinkel","year":"1958","journal-title":"Cancer Res"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0505","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1093\/jnci\/94.24.1822","article-title":"Body Surface Area in Dosing Anticancer Agents: Scratch the Surface!","volume":"94","author":"Miller","year":"2002","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0510","first-page":"219","article-title":"Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man","volume":"50","author":"Freireich","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0515","unstructured":"FDA. LUPRON DEPOT (leuprolide acetate for depot suspension). 31 (2014)."},{"key":"10.1016\/j.jconrel.2022.10.043_bb0520","doi-asserted-by":"crossref","first-page":"1705328","DOI":"10.1002\/adma.201705328","article-title":"Advances in Biomaterials for Drug Delivery","volume":"30","author":"Fenton","year":"2018","journal-title":"Advanced Materials"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0525","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/jnci\/82.4.323","article-title":"Is dose normalization to weight or body surface area useful in adults?","volume":"82","author":"Grochow","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0530","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1126\/science.aax7621","article-title":"Dosing time matters","volume":"365","author":"Ruben","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0535","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/jnci\/86.21.1608","article-title":"Chronomodulated Versus Fixed-Infusion\u2014Rate Delivery of Ambulatory Chemotherapy With Oxaliplatin, Fluorouracil, and Folinic Acid (Leucovorin) in Patients With Colorectal Cancer Metastases: a Randomized Multi-institutional Trial","volume":"86","author":"L\u00e9vi","year":"1994","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0540","unstructured":"Research, C. for D. E. and. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Food and Drug Administration https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers (2018)."},{"key":"10.1016\/j.jconrel.2022.10.043_bb0545","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2022.10.043_bb0550","author":"Washington University School of Medicine"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0555","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/BF00587008","article-title":"Human surface area: Comparison of the du bois formula with direct photometric measurement","volume":"325","author":"Mitchell","year":"1971","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.jconrel.2022.10.043_bb0560","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1001\/archpedi.152.4.340","article-title":"Errors in the Use of Medication Dosage Equations","volume":"152","author":"Lesar","year":"1998","journal-title":"Archives of Pediatrics & Adolescent Medicine"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0565","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jama.1997.03540280050033","article-title":"Factors Related to Errors in Medication Prescribing","volume":"277","author":"Lesar","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0570","unstructured":"Cusack Jr., J. C., Overman, M. J. & Kunitake, H. Treatment of small bowel neoplasms. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on January 27, 2021)."},{"key":"10.1016\/j.jconrel.2022.10.043_bb0575","doi-asserted-by":"crossref","DOI":"10.1038\/srep27966","article-title":"Body surface area formulae: an alarming ambiguity","volume":"6","author":"Redlarski","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0580","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd3801","article-title":"The determination and interpretation of the therapeutic index in drug development","volume":"11","author":"Muller","year":"2012","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0585","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00280-016-3054-2","article-title":"Therapeutic drug monitoring of 5-fluorouracil","volume":"78","author":"Lee","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.jconrel.2022.10.043_bb0590","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/jamaoncol.2019.4668","article-title":"Body composition, adherence to anthracycline and taxane-based chemotherapy, and survival after nonmetastatic breast cancer","volume":"6","author":"Cespedes Feliciano","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0595","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clcc.2013.11.001","article-title":"Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens","volume":"13","author":"Kline","year":"2014","journal-title":"Clinical Colorectal Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0600","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.e19562","article-title":"Point-of-care (POC) diagnostic assay for 5-fluorouracil (5-FU) quantitation to enable dose adjustment and detect dihydropyrimidine dehydrogenase (DPD) deficiency","volume":"29","author":"White","year":"2011","journal-title":"JCO"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0605","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/sj.bjc.6600139","article-title":"How to calculate the dose of chemotherapy","volume":"86","author":"Gurney","year":"2002","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0610","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/jjco\/hyp176","article-title":"Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis","volume":"40","author":"Watayo","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0615","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/j.seminoncol.2017.02.007","article-title":"A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification","volume":"44","author":"Boisdron-Celle","year":"2017","journal-title":"Seminars in Oncology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0620","article-title":"Making Fluorouracil \u201cSexy\u201d Again","author":"Boland","year":"2020","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0625","unstructured":"Lexicomp, Inc. Fluorouracil (systemic): Drug information. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on February 01, 2022)."},{"key":"10.1016\/j.jconrel.2022.10.043_bb0630","series-title":"Rowland and Tozer\u2019s Clinical Pharmacokinetics and Pharmacodynamics","author":"Derendorf","year":"2020"},{"issue":"4","key":"10.1016\/j.jconrel.2022.10.043_bb0635","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage","volume":"17","author":"Gamelin","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0640","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/jnci\/djp328","article-title":"Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes","volume":"101","author":"Saif","year":"2009","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0645","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/clpt.1994.123","article-title":"Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: Relationship with mucosal toxicity in patients with cancer","volume":"56","author":"Metzger","year":"1994","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0650","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6600208","article-title":"Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene","volume":"86","author":"Maring","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0655","first-page":"5","volume":"4","author":"Rohatgi","year":"2021","journal-title":"WebPlotDigitizer v"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0660","series-title":"Proc. of the 9th Python in Science Conf.","doi-asserted-by":"crossref","first-page":"56","DOI":"10.25080\/Majora-92bf1922-00a","article-title":"Data Structures for Statistical Computing in Python","volume":"445","author":"McKinney","year":"2010"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0665","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1109\/MCSE.2007.55","article-title":"Matplotlib: A 2D Graphics Environment","volume":"9","author":"Hunter","year":"2007","journal-title":"Computing in Science Engineering"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0670","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/bcp.13007","article-title":"Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers","volume":"82","author":"Jacobs","year":"2016","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0675","first-page":"197","article-title":"Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion","volume":"50","author":"Harris","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0680","first-page":"6193","article-title":"Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer","volume":"35","author":"Matsumoto","year":"2015","journal-title":"Anticancer Research"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0685","first-page":"1507","article-title":"Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"6","author":"Chen","year":"2013","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0690","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2532::AID-CNCR7>3.0.CO;2-1","article-title":"A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma","volume":"85","author":"L\u00e9vi","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0695","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.molmed.2016.03.004","article-title":"Dosing-time makes the poison: circadian regulation and pharmacotherapy","volume":"22","author":"Dallmann","year":"2016","journal-title":"Trends in Molecular Medicine"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0700","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10549-015-3452-x","article-title":"Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients","volume":"152","author":"Binkhorst","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0705","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40262-015-0239-5","article-title":"Relationship between sunitinib pharmacokinetics and administration time: preclinical and clinical evidence","volume":"54","author":"Kloth","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0710","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.addr.2006.11.001","article-title":"Implications of circadian clocks for the rhythmic delivery of cancer therapeutics","volume":"59","author":"L\u00e9vi","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0715","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev.pharmtox.48.113006.094626","article-title":"Circadian timing in cancer treatments","volume":"50","author":"L\u00e9vi","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2022.10.043_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114045","article-title":"Circadian rhythm in pharmacokinetics and its relevance to chronotherapy","volume":"178","author":"Dong","year":"2020","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0725","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1470-2045(00)00326-0","article-title":"Circadian chronotherapy for human cancers","volume":"2","author":"L\u00e9vi","year":"2001","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0730","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1056\/NEJMra1802337","article-title":"Circadian mechanisms in medicine","volume":"384","author":"Allada","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0735","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1073\/pnas.1314066111","article-title":"Circadian clock-dependent and -independent rhythmic proteomes implement distinct diurnal functions in mouse liver","volume":"111","author":"Mauvoisin","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0740","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004047","article-title":"In-vivo quantitative proteomics reveals a key contribution of post-transcriptional mechanisms to the circadian regulation of liver metabolism","volume":"10","author":"Robles","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0745","doi-asserted-by":"crossref","first-page":"16219","DOI":"10.1073\/pnas.1408886111","article-title":"A circadian gene expression atlas in mammals: Implications for biology and medicine","volume":"111","author":"Zhang","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0750","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1073\/pnas.1114410109","article-title":"The human circadian metabolome","volume":"109","author":"Dallmann","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0755","author":"CircadiOmics"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0760","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nmeth.2111","article-title":"CircadiOmics: integrating circadian genomics, transcriptomics, proteomics and metabolomics","volume":"9","author":"Patel","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0765","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: a review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jconrel.2022.10.043_bb0770","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.sla.0000193599.57858.9b","article-title":"CASH (Chemotherapy-Associated Steatohepatitis) Costs","volume":"243","author":"Fong","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0775","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1038\/bjc.1998.333","article-title":"Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer","volume":"77","author":"Peppercorn","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0780","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0140-6736(20)30540-7","article-title":"The link between kidney disease and cancer: complications and treatment","volume":"396","author":"Malyszko","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0785","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0959-8049(97)00340-7","article-title":"Pharmacokinetics of anticancer agents in patients with impaired liver function","volume":"34","author":"Donelli","year":"1998","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0790","first-page":"253","article-title":"Chronic kidney disease and cancer: a troubling connection","volume":"23","author":"Stengel","year":"2010","journal-title":"J Nephrol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0795","article-title":"Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience","author":"Oleas","year":"2020","journal-title":"Clinical Kidney Journal"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0800","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2017.72.7578","article-title":"New model for estimating glomerular filtration rate in patients with cancer","volume":"35","author":"Janowitz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0805","author":"CKD-EPI Adults (Conventional Units) | NIDDK"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0810","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41416-019-0423-8","article-title":"The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study","volume":"120","author":"Iachetta","year":"2019","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0815","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0820","series-title":"Handbook of Pharmacogenomics and Stratified Medicine","first-page":"341","article-title":"Chapter 17 - Pharmacokinetic Pharmacogenomics","author":"Alsanosi","year":"2014"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0825","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2217\/pgs.11.72","article-title":"Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity","volume":"12","author":"Amstutz","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0830","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0835","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1172\/JCI113308","article-title":"Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity","volume":"81","author":"Diasio","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0840","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","article-title":"Clinical pharmacology of 5-fluorouracil","volume":"16","author":"Diasio","year":"1989","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0845","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/17425250902800153","article-title":"Ethnic differences in drug metabolism and toxicity from chemotherapy","volume":"5","author":"Phan","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0850","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0090-9556(24)15065-9","article-title":"Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil","volume":"28","author":"Kanamitsu","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0855","first-page":"270","article-title":"Lethal drug interactions of sorivudine, a new antiviral drug, with Oral 5-fluorouracil prodrugs","volume":"25","author":"Okuda","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0860","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/dmd.104.001032","article-title":"Relationships among plasma [2-(13)C]uracil concentrations, breath (13)CO(2) expiration, and dihydropyrimidine dehydrogenase (DPD) activity in the liver in normal and dpd-deficient dogs","volume":"33","author":"Inada","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0865","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjc.6601973","article-title":"Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation","volume":"91","author":"Milano","year":"2004","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0870","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1200\/JCO.2002.20.6.1683","article-title":"Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors","volume":"20","author":"Adjei","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0875","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.1998.16.4.1450","article-title":"Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer","volume":"16","author":"Schilsky","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0880","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00280-002-0536-1","article-title":"A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005)","volume":"51","author":"O\u2019Donnell","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0885","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1200\/JCO.2002.20.6.1519","article-title":"Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic\/advanced colorectal cancer","volume":"20","author":"Schilsky","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0890","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat9931","article-title":"Separating host and microbiome contributions to drug pharmacokinetics and toxicity","volume":"363","author":"Zimmermann","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0895","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.tips.2019.04.014","article-title":"Predicting and Understanding the Human Microbiome\u2019s Impact on Pharmacology","volume":"40","author":"Hitchings","year":"2019","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0900","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.cell.2020.05.001","article-title":"Personalized Mapping of Drug Metabolism by the Human Gut Microbiome","volume":"181","author":"Javdan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0905","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.1038\/s41598-020-60982-8","article-title":"Manipulation of the Gut Microbiome Alters Acetaminophen Biodisposition in Mice","volume":"10","author":"Malfatti","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0910","doi-asserted-by":"crossref","DOI":"10.1126\/science.aag2770","article-title":"Chemical transformation of xenobiotics by the human gut microbiota","volume":"356","author":"Koppel","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0915","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1126\/science.1191175","article-title":"Alleviating cancer drug toxicity by inhibiting a bacterial enzyme","volume":"330","author":"Wallace","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0920","first-page":"5137","article-title":"Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters","volume":"58","author":"Chu","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0925","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/03602532.2018.1497647","article-title":"Gut microbiota modulates drug pharmacokinetics","volume":"50","author":"Zhang","year":"2018","journal-title":"Drug Metabolism Reviews"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0930","doi-asserted-by":"crossref","unstructured":"Schmetzer, O. & Fl\u00f6rcken, A. Sex Differences in the Drug Therapy for Oncologic Diseases. in Sex and Gender Differences in Pharmacology (ed. Regitz-Zagrosek, V.) 411\u2013442 (Springer, 2012). doi:https:\/\/doi.org\/10.1007\/978-3-642-30726-3_19.","DOI":"10.1007\/978-3-642-30726-3_19"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0935","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00280-012-2018-4","article-title":"Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study","volume":"71","author":"Mueller","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0940","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s002800050980","article-title":"Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer","volume":"44","author":"Bressolle","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0945","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/1078155217732141","article-title":"Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature","volume":"25","author":"Zurayk","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0950","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00280-016-3063-1","article-title":"Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency","volume":"78","author":"Saif","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0955","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.30321","article-title":"Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity","volume":"123","author":"Ma","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0960","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00280-015-2804-x","article-title":"Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis","volume":"76","author":"Li","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0965","first-page":"E4777","article-title":"Cisplatin-DNA adduct repair of transcribed genes is controlled by two circadian programs in mouse tissues","volume":"115","author":"Yang","year":"2018","journal-title":"PNAS"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0970","first-page":"1996","article-title":"Experimental chronotherapy of mouse mammary adenocarcinoma MA13\/C with docetaxel and doxorubicin as single agents and in combination","volume":"61","author":"Granda","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0975","doi-asserted-by":"crossref","first-page":"8448","DOI":"10.1158\/0008-5472.CAN-05-1161","article-title":"Therapeutic Index by Combination of Adriamycin and Docetaxel Depends on Dosing Time in Mice","volume":"65","author":"Tabuchi","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0980","first-page":"3896","article-title":"Docetaxel chronopharmacology in mice","volume":"58","author":"Tampellini","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0985","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40262-013-0121-2","article-title":"Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients","volume":"53","author":"Salem","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0990","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00315211","article-title":"Chronopharmacokinetics of doxorubicin in patients with breast cancer","volume":"40","author":"Canal","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb0995","doi-asserted-by":"crossref","first-page":"95780","DOI":"10.1039\/C6RA13854C","article-title":"Chronopharmacokinetics and mechanisms of gefitinib in a nude mice model of non-small cell lung cancer","volume":"6","author":"Wang","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2022.10.043_bb1000","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3109\/07420528.2015.1022782","article-title":"The effect of circadian rhythm on pharmacokinetics and metabolism of the Cdk inhibitor, roscovitine, in tumor mice model","volume":"32","author":"Sallam","year":"2015","journal-title":"Chronobiol Int"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1005","first-page":"1135","article-title":"Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia","volume":"144","author":"Koren","year":"1990","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/BF00689702","article-title":"Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology","volume":"28","author":"Hassan","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.clpt.6100297","article-title":"Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients","volume":"83","author":"Etienne-Grimaldi","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1020","series-title":"Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype\u2013Guided Dosing. Clin Cancer Res","first-page":"18","article-title":"Clinical Assessment of 5-Fluorouracil\/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX)","volume":"26","author":"Joshi","year":"2020"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/sj.bjc.6603860","article-title":"Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?","volume":"97","author":"Ueno","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1030","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40262-016-0450-z","article-title":"Genotypes Affecting the Pharmacokinetics of Anticancer Drugs","volume":"56","author":"Bertholee","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1035","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/00001813-200010000-00001","article-title":"Gender-dependent pharmacokinetics of topotecan in adult patients","volume":"11","author":"Loos","year":"2000","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1040","first-page":"263","article-title":"Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study","volume":"11","author":"Capitain","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1045","doi-asserted-by":"crossref","first-page":"25913","DOI":"10.1038\/srep25913","article-title":"Pharmacokinetically guided algorithm of 5-fluorouracil dosing, a reliable strategy of precision chemotherapy for solid tumors: a meta-analysis","volume":"6","author":"Fang","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1050","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0168-3659(85)90058-6","article-title":"Triggered drug delivery systems","volume":"2","author":"Pitt","year":"1985","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1055","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/FTD.0b013e3181b9b8c0","article-title":"Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer","volume":"31","author":"Beumer","year":"2009","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clcc.2014.09.007","article-title":"Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer","volume":"13","author":"Goldstein","year":"2014","journal-title":"Clinical Colorectal Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1065","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of Therapeutic Drug Monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1075","first-page":"681","article-title":"Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer","volume":"350","author":"L\u00e9vi","year":"1997","journal-title":"International Organization for Cancer Chronotherapy. Lancet"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1080","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1021\/bi5007354","article-title":"Circadian clock, cancer, and chemotherapy","volume":"54","author":"Sancar","year":"2015","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1085","doi-asserted-by":"crossref","first-page":"E9247","DOI":"10.1073\/pnas.1800314115","article-title":"Universal method for robust detection of circadian state from gene expression","volume":"115","author":"Braun","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1090","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2017.00369","article-title":"Circadian metabolomics in time and space","volume":"11","author":"Dyar","year":"2017","journal-title":"Front Neurosci"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1095","unstructured":"Dean, L. & Kane, M. Fluorouracil Therapy and DPYD Genotype. in Medical Genetics Summaries (eds. Pratt, V. M. et al.) (National Center for Biotechnology Information (US), 2012)."},{"key":"10.1016\/j.jconrel.2022.10.043_bb1100","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/OP.20.00553","article-title":"All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide","volume":"16","author":"Innocenti","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1105","first-page":"628","article-title":"Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper","volume":"43","author":"W\u00f6rmann","year":"2020","journal-title":"ORT"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12885-022-09171-6","article-title":"Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation","volume":"22","author":"Lau-Min","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1115","first-page":"53","article-title":"Pharmacogenetics implementation in the clinics: information and guidelines for germline variants","volume":"2","author":"Olivera","year":"2019","journal-title":"Cancer Drug Resistance"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1120","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/bjc.2016.189","article-title":"Sporadic colorectal cancer: microbial contributors to disease prevention, development and therapy","volume":"115","author":"Drewes","year":"2016","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1125","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature15817","article-title":"Pharmacogenomics in the clinic","volume":"526","author":"Relling","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41551-017-0070","article-title":"Closed-loop control of circulating drug levels in live animals","volume":"1","author":"Mage","year":"2017","journal-title":"Nature Biomedical Engineering"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0169-409X(00)00136-8","article-title":"Responsive polymeric delivery systems","volume":"46","author":"Kost","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0168-3659(88)90037-5","article-title":"Chemically self-regulated drug delivery systems","volume":"8","author":"Heller","year":"1988","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1145","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0167-7799(92)90194-Z","article-title":"Responsive polymer systems for controlled delivery of therapeutics","volume":"10","author":"Kost","year":"1992","journal-title":"Trends in Biotechnology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1150","series-title":"Process Dynamics and Control","author":"Seborg","year":"2011"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1155","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.2337\/db11-0654","article-title":"Artificial Pancreas: Past, Present","volume":"60","author":"Cobelli","year":"2011","journal-title":"Future. Diabetes"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1160","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1021\/acsptsci.8b00033","article-title":"High-precision control of plasma drug levels using feedback-controlled dosing","volume":"1","author":"Arroyo-Curr\u00e1s","year":"2018","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.jconrel.2022.10.043_bb1165","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics","volume":"9","author":"Keefe","year":"2010","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1170","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.bioeng.2007.06.001","article-title":"SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands","volume":"24","author":"Stoltenburg","year":"2007","journal-title":"Biomol Eng"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41570-017-0076","article-title":"Analysis of aptamer discovery and technology","volume":"1","author":"Dunn","year":"2017","journal-title":"Nature Reviews Chemistry"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1180","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1073\/pnas.1424684112","article-title":"Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates","volume":"112","author":"Chou","year":"2015","journal-title":"PNAS"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1185","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41570-017-0063","article-title":"Evolution of macromolecular complexity in drug delivery systems","volume":"1","author":"Kakkar","year":"2017","journal-title":"Nature Reviews Chemistry"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1195","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nature Reviews Materials"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1205","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.addr.2013.09.001","article-title":"Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities","volume":"65","author":"Kirtane","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1210","author":"Human Metabolome Database"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1215","author":"SMPDB"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1220","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1225","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/s41579-019-0256-8","article-title":"Diet\u2013microbiota interactions and personalized nutrition","volume":"17","author":"Kolodziejczyk","year":"2019","journal-title":"Nature Reviews Microbiology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1230","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41577-020-0374-6","article-title":"Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?","volume":"20","author":"Finlay","year":"2020","journal-title":"Nature Reviews Immunology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1235","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41591-020-0882-8","article-title":"Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer","volume":"26","author":"Roberti","year":"2020","journal-title":"Nature Medicine"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1240","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrd2683","article-title":"Mechanisms of drug combinations: interaction and network perspectives","volume":"8","author":"Jia","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1245","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00262-012-1388-0","article-title":"Chemoimmunotherapy: reengineering tumor immunity","volume":"62","author":"Chen","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1250","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/emboj.2009.1","article-title":"Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death","volume":"28","author":"Panaretakis","year":"2009","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1255","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell\u2013Dependent Antitumor Immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1260","doi-asserted-by":"crossref","first-page":"6984948","DOI":"10.1155\/2018\/6984948","article-title":"Anti-PD-1\/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies","volume":"2018","author":"Sui","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1265","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3390\/biomedicines9111591","article-title":"Targeted Therapies in Cancer: To Be or Not to Be","volume":"9","author":"Montoya","year":"2021","journal-title":"Selective. Biomedicines"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1270","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41591-019-0376-8","article-title":"Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer","volume":"25","author":"Mohammad","year":"2019","journal-title":"Nature Medicine"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1275","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41568-020-00307-z","article-title":"Mutations and mechanisms of WNT pathway tumour suppressors in cancer","volume":"21","author":"Bugter","year":"2021","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1280","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","article-title":"Synthetic lethality as an engine for cancer drug target discovery","volume":"19","author":"Huang","year":"2020","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1285","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates\u2014an emerging class of cancer treatment","volume":"114","author":"Diamantis","year":"2016","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1290","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3390\/molecules25030745","article-title":"The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules","volume":"25","author":"de la Torre","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1295","article-title":"2020 FDA drug approvals","author":"Mullard","year":"2021","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1300","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12943-017-0683-y","article-title":"Nano-based delivery of RNAi in cancer therapy","volume":"16","author":"Xin","year":"2017","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1305","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0014-5793(03)00523-4","article-title":"Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)","volume":"545","author":"Nieth","year":"2003","journal-title":"FEBS Letters"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1310","doi-asserted-by":"crossref","first-page":"18638","DOI":"10.1073\/pnas.1303958110","article-title":"Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug","volume":"110","author":"Xu","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1315","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the \u2018undruggable\u2019 cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1320","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-pharmtox-010715-103633","article-title":"RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?","volume":"56","author":"Bobbin","year":"2016","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1325","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2016.05.010","article-title":"Delivery Strategies and Potential Targets for siRNA in Major Cancer Types","volume":"104","author":"Lee","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1330","doi-asserted-by":"crossref","first-page":"eabm5551","DOI":"10.1126\/science.abm5551","article-title":"Massively parallel pooled screening reveals genomic determinants of nanoparticle delivery","volume":"377","author":"Boehnke","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1335","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41565-021-00870-y","article-title":"Computationally guided high-throughput design of self-assembling drug nanoparticles","volume":"16","author":"Reker","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2022.10.043_bb1340","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1073\/pnas.1620874114","article-title":"Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics","volume":"114","author":"Dahlman","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1345","doi-asserted-by":"crossref","first-page":"1902798","DOI":"10.1002\/adma.201902798","article-title":"Using Large Datasets to Understand Nanotechnology","volume":"31","author":"Paunovska","year":"2019","journal-title":"Advanced Materials"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1350","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41565-022-01146-9","article-title":"Nanoparticle single-cell multiomic readouts reveal that cell heterogeneity influences lipid nanoparticle-mediated messenger RNA delivery","volume":"17","author":"Dobrowolski","year":"2022","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2022.10.043_bb1355","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1073\/pnas.93.9.4192","article-title":"Converting cancer genes into killer genes","volume":"93","author":"Costa","year":"1996","journal-title":"PNAS"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1360","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3121\/cmr.4.3.218","article-title":"Gene Therapy for Cancer Treatment: Past Present and Future","volume":"4","author":"Cross","year":"2006","journal-title":"Clin Med Res"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1365","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1370","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1375","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1380","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1385","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","article-title":"The tangled history of mRNA vaccines","volume":"597","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1390","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1395","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther Deliv"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1400","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101142","article-title":"Role of nanotechnology behind the success of mRNA vaccines for COVID-19","volume":"38","author":"Khurana","year":"2021","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1405","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41570-018-0039-1","article-title":"Synthetic materials at the forefront of gene delivery","volume":"2","author":"Lostal\u00e9-Seijo","year":"2018","journal-title":"Nature Reviews Chemistry"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1410","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/21691401.2017.1307210","article-title":"Advances in siRNA delivery in cancer therapy","volume":"46","author":"Singh","year":"2018","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1415","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/d41573-020-00220-y","article-title":"Exosome-based candidates move into the clinic","volume":"20","author":"Cully","year":"2020","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1420","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1425","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41568-020-00299-w","article-title":"The evolving translational potential of small extracellular vesicles in cancer","volume":"20","author":"M\u00f6ller","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1430","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature22341","article-title":"Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer","volume":"546","author":"Kamerkar","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1435","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1440","unstructured":"Transformative Exosome Therapeutics. Evox Therapeutics https:\/\/www.evoxtherapeutics.com."},{"key":"10.1016\/j.jconrel.2022.10.043_bb1445","unstructured":"Home \u2022 Codiak Biosciences. Codiak Biosciences https:\/\/www.codiakbio.com\/."},{"key":"10.1016\/j.jconrel.2022.10.043_bb1450","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41578-020-00277-6","article-title":"Extracellular vesicles versus synthetic nanoparticles for drug delivery","volume":"6","author":"Witwer","year":"2021","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1455","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.7150\/thno.37097","article-title":"Extracellular vesicle-based drug delivery systems for cancer treatment","volume":"9","author":"Walker","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1460","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2022.10.043_bb1465","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/s41563-021-01047-7","article-title":"Obstacles and opportunities in a forward vision for cancer nanomedicine","volume":"20","author":"de L\u00e1zaro","year":"2021","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2022.10.043_bb1470","article-title":"Cancer nanomedicine","volume":"1\u20137","author":"Bhatia","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1475","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010564","article-title":"An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors","volume":"7","author":"Jonas","year":"2015","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1480","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1109\/TBME.2021.3096126","article-title":"The Translational and Regulatory Development of an Implantable Microdevice for Multiple Drug Sensitivity Measurements in Cancer Patients","volume":"69","author":"Dominas","year":"2022","journal-title":"IEEE Transactions on Biomedical Engineering"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1485","article-title":"First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Non-Small Cell Lung Cancer","author":"Tsai","year":"2022","journal-title":"Annals of Surgery"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1490","article-title":"A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs","volume":"1\u201311","author":"Tatarova","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1495","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1349-7006.2006.00287.x","article-title":"Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma","volume":"97","author":"Nozawa","year":"2006","journal-title":"Cancer Science"},{"key":"10.1016\/j.jconrel.2022.10.043_bb1500","first-page":"1258","article-title":"Intensive combination chemotherapy and X-irradiation in Hodgkin\u2019s disease","volume":"27","author":"Moxley","year":"1967","journal-title":"Cancer Res"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922007210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922007210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:41:30Z","timestamp":1759164090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922007210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":300,"alternative-id":["S0168365922007210"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.10.043","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The past, present, and future of chemotherapy with a focus on individualization of drug dosing","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.10.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}